drugset / Trial / NCT03475186
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Phase 2
Completed
75 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care
Summary
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
Timeline
- Start
- 2019-03-25
- Primary completion
- 2025-03-25
- Completion
- 2025-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramipril | Small molecule | 2.5 mg | Oral |
| Subject | Ramipril | Small molecule | 5 mg | Oral |